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Genome-wide association study identiﬁes variation
at 6q25.1 associated with survival in multiple
myeloma
David C. Johnson1,*, Niels Weinhold2,3,*, Jonathan S. Mitchell4,*, Bowang Chen5, Martin Kaiser1, Dil B. Begum1,
Jens Hillengass3, Uta Bertsch3, Walter A. Gregory6, David Cairns6, Graham H. Jackson7, Asta Fo¨rsti5,8,
Jolanta Nickel3, Per Hoffmann9,10, Markus M. No¨ethen9,11, Owen W. Stephens2, Bart Barlogie2, Faith E. Davis2,
Kari Hemminki5,8,**, Hartmut Goldschmidt3,12,**, Richard S. Houlston1,4,** & Gareth J. Morgan2,**
Survival following a diagnosis of multiple myeloma (MM) varies between patients and some
of these differences may be a consequence of inherited genetic variation. In this study,
to identify genetic markers associated with MM overall survival (MM-OS), we conduct a
meta-analysis of four patient series of European ancestry, totalling 3,256 patients with 1,200
MM-associated deaths. Each series is genotyped for B600,000 single nucleotide
polymorphisms across the genome; genotypes for six million common variants are imputed
using 1000 Genomes Project and UK10K as the reference. The association between genotype
and OS is assessed by Cox proportional hazards model adjusting for age, sex, International
staging system and treatment. We identify a locus at 6q25.1 marked by rs12374648
associated with MM-OS (hazard ratio¼ 1.34, 95% conﬁdence interval¼ 1.22–1.48,
P¼4.69 10–9). Our ﬁndings have potential clinical implications since they demonstrate that
inherited genotypes can provide prognostic information in addition to conventional tumor
acquired prognostic factors.
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M
ultiple myeloma (MM) is a malignancy characterized by
the inﬁltration of clonal plasma cells in the bone
marrow1,2. There is considerable heterogeneity in
the survival outcomes among MM patients and a variety of
clinical features and tumour biomarkers have been shown to be
predictive of prognosis3–8.
As a potential prognostic factor, the concept of germline variation
imparting inter-individual variability in tumour development and
progression is receiving increasing attention9–12. This observation is
exempliﬁed by breast cancer where a more accurate assessment of
prognosis can be made by taking into account genetic information
to improve therapeutic decision making, opening up the possibility
of patient-tailored drug selection decisions13. In addition, detecting
genes with prognostic relevance has the potential to aid the
identiﬁcation of pathways that could be targeted for novel
therapeutic interventions.
Here to identify germline variation inﬂuencing patient
outcome following a diagnosis of MM we have pooled genotype
data from four independent genome-wide association studies
(GWAS) of MM14–17 and linked these to survival time data. Our
ﬁndings are consistent with the hypothesis that an individual’s
prognosis following treatment for MM is inﬂuenced by germline
variation. Speciﬁcally, we identiﬁed a locus at 6q25.1
(rs12374648) associated with MM-OS that was statistically
signiﬁcant. Moreover, the association at 6q25.1 was consistently
seen in each of the four patient cohorts and was not conﬁned to a
speciﬁc molecular subtype of MM.
Results
Genome-wide association study. After applying quality control
measures, genotype data were available on 3,256 cases from the
GWAS series, Supplementary Figs 1 and 2. The inﬂation factor
four l for each of the studies ranged from 0.99 to 1.03 and for
the overall analysis was 1.02 (Supplementary Figs 3 and 4).
We identiﬁed eight single nucleotide polymorphisms (SNPs)
associated with MM-OS at P values r5.0 10 8; proportional
hazards model. All eight SNPs were located on chromosome
6q25.1 and were in linkage disequilibrium (r2¼ 0.58–1.0), Figs 1
and 2. The strongest association was provided by rs12748648
(P¼ 4.89 10 9, hazard ratio (HR)¼ 1.34, 95% conﬁdence
interval (CI)¼ 1.22–1.48, risk allele frequency¼ 0.19); Table 1,
Fig. 2 and Supplementary Fig. 5. The association was consistent
across the four series and there was very little between-study
heterogeneity (P¼ 0.34, I2¼ 11%; test of heterogeneity).
Homozygosity for rs12748648 GG was associated with median
survival time of 26.7 (UK-My9), 42.8 (GER-German-speaking
Myeloma Multicenter Study Group (GMMG)) and 80
(US-University of Arkansas for Medical Sciences (UAMS))
months as compared with 60, 92.2 and 137 months, respectively,
for patients homozygous for AA genotype (Fig. 3). To address the
possibility that the impact of rs12748648 on MM-OS is a con-
sequence of its association with known cytogenetic risk factors we
performed a multivariate analysis on the 1,165 patients of the
UK-My9 cohort including rs12748648, high-risk IgH transloca-
tions, gain(1q21) and del(17p). This showed that 6p25.1
(rs12374648) independently impacted MM-OS (Supplementary
Table 1). Patients with complete remission after autologous cell
transplant (ASCT) tend to have a better survival. We examined
whether the 6q25.1 association for OS was conﬁned to patients
with or without complete remission and we found the association
was apparent in both patient groups (P¼ 0.84; test of
heterogeneity).
Overall survival risk allele for myeloma at 6p25.1. rs12748648
maps within a 49.2-Kb (r240.2) region of linkage disequilibrium
intergenic to MTHFD1L and AKAP12 genes (Fig. 2). The
genomic region contains multiple enhancer marks and the SNP
localizes to a predicted enhancer element that is bound by TCF4
(TCF7L2), Supplementary Fig. 5. Analysis of eQTL data did not
demonstrate a relationship between rs12748648 genotype and
expression of MTHFD1L, AKAP12 or distantly ﬂanking genes
(Supplementary Figs 6 and 7). Examining encyclopedia of DNA
elements (ENCODE) CHIP-seq data in the lymphoblast cell line
GM12878 of the 6p25.1 showed that rs12748648 maps to region
enriched for H3K27me3, a polycomb repressive mark. As DNA
methylation can have a role in access of such polycomb repres-
sion18, we undertook a meQTL analysis of the region around
rs12748648. We found an association between rs12748648 risk
genotype and reduced methylation of both MTHFD1L and
AKAP12 genes (P¼ 0.0077 and 0.0097, respectively, log-linear
regression; Supplementary Fig. 8). In addition to the 6q25.1
(rs12748648) association for MM-OS we identiﬁed suggestive
associations (that is Po10 5; proportional hazards model) at
1q23.3 (rs1934908), 19q13.11 (rs1974807), 5q31.3 (rs2906053),
3q13 (rs4682170), 18q21 (rs57942319) and 2q22 (rs61070260;
Supplementary Table 2 and Supplementary Figs 9–20). All of the
SNPs deﬁning these associations mapped to genomic regions with
regulatory marks (Supplementary Table 3), with rs1934908
impacting FCLRA expression in plasma cells (Supplementary
Fig. 21).
All of the SNP associations noted above for MM-OS showed a
consistent effect on progression-free survival, Supplementary
Table 4. It is possible that some of the inherited genetic
variants that impact on the risk of developing MM14,16,17,19,
may also impact on MM-OS. To address this possibility we
examined the relationship between previously published risk
SNPs and MM-OS. None of the nine validated risk SNPs for MM
were associated with MM-OS, that is, P40.05, proportional
hazards model; Supplementary Table 5.
Discussion
Our ﬁndings suggest a hypothesis that an individual’s prognosis
following treatment for MM is inﬂuenced by germline variation.
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Figure 1 | Association plot for combined analyses for MM-OS. The
P-values of the association between each SNP and myeloma survival were
obtained by Cox regression analyses with adjustment and then combined.
The y axis shows the  log10 P-values of each SNP analysed, and the x axis
shows their respective chromosome position. The red horizontal line
corresponds to P¼ 5.0 10 8. All statistical tests were two-sided.
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In our analysis we adjusted for the inﬂuence of treatment on
survival within studies, and report associations consistent across
the four studies, thus our ﬁndings are likely to relate to
underlying biology impacting the survival of the myeloma clone.
The treatment used in all of the studies included ASCT, the
GMMG studies used a tandem transplant, younger patients in the
Medical Research Council (MRC) study received a single ASCT
in both the Myeloma IX (UK-My9) and Myeloma IX (UK-My11)
cases. The UAMS (US-UAMS) cases received predominantly
tandem transplants together with combination induction and
consolidation therapy. Prognostic factors generated from these
studies are generally applicable to patients treated with ASCT and
the use of novel agents including lenalidomide and bortezomib
used as both induction and maintenance.
The 6q25.1 locus that associates with MM-OS spans a region of
LD intergenic to MTHFD1L and AKAP12 genes. While variation
at 6q25.1 has previously been linked to coronary heart disease20,21
(rs6922269) and late-onset Alzheimer disease22 (rs11754661)
the risk SNPs for these diseases are not correlated with
rs12574648 (respective LD metrics–r2¼ 0.002, D0 ¼ 0.08 and
r2¼ 0.046, D0 ¼ 0.65). MTHFD1L is involved in mitochondrial
tetrahydrofolate (THF) synthesis23,24. One-carbon substituted
forms of THF are important for the de novo synthesis of purines
and thymidylate supporting cellular methylation by regenerating
methionine from homocysteine. There have been no previous
reports of associations of cancer risk or overall survival (OS) with
variation at AKAP12, but AKAP12 has been shown to be a
tumour suppressor, acting through CyclinD1 (ref. 25). AKAP12 is
regulated by methylation in a number of cancers26–33 and is
epigenetically repressed in MM, where its expression can be
upregulated following treatment with DNA demethylation
compounds such as trichostatin and/or 5-aza-20-deoxycytidine34.
Intriguingly, although rare, 6q is a site of recurrent deletion in
lymphoid tumours, that includes homozygous deletions at 6q25.3
(AR1D1B/WTAP)35 and mutations at 6q21 (PRDM1/BLIMP1)36–
38. It is however unlikely that any somatic mutations in this
regions are responsible for the MM-OS signal. While the
functional basis for the rs12374648 remains to be established
the SNP maps to a binding site for the transcription factor
TCF7L2, alias TCF4. Binding of TCF7L2 correlates with
hypomethylation and contributes to formation of differentially
methylated regions of the genome39; TCF7L2 is commonly bound
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Figure 2 | Regional plot of association results and recombination rates for the rs12374648 (6q25.1) MM-OS risk locus. Plots show association results
of both genotyped (triangles) and imputed (circles) SNPs in the GWAS samples and recombination rates.  log10 P-values (y axes) of the SNPs are shown
according to their chromosomal positions (x axes). The top genotyped SNP in each combined analysis is shown as a large diamond and is labelled by its
rsID. The colour intensity of each symbol reﬂects the extent of LD with the top genotyped SNP, white (r2¼0) through to dark red (r2¼ 1.0). Genetic
recombination rates, estimated using HapMap samples from Utah residents of western and northern European ancestry (CEU), are shown with a light blue
line. Physical positions are based on NCBI build 37 of the human genome. Also shown are the relative positions of genes and transcripts mapping to the
region of association. Genes have been redrawn to show their relative positions; therefore, maps are not to physical scale. Below each plot is a diagram of
the exons and introns of the genes of interest.
Table 1 | Summary result for the combined analysis of 6q25.1 (rs12374648) and MM-OS.
SNP Base pair Risk allele Study RAF N Events Genoytypes HR (95% CI) P-value
rs12374648 (6q25.1) 151529369 G GG AG AA
UK-My9 0.19 1,163 510 38 367 758 1.45 (1.24–1.68) 1.69 10 6
UK-My11 0.19 871 201 28 283 560 1.39 (1.10–1.75) 0.006
GER-GMMG 0.20 508 156 18 164 326 1.09 (0.82–1.44) 0.55
US-UAMS 0.20 702 330 30 218 454 1.28 (1.06–1.54) 0.009
Combined 1.34 (1.22–1.48) 4.69 10 9
Phet¼0.34, I2¼ 11%
RAF, risk allele frequency.
The P-values of the association between each SNP and myeloma survival were obtained by Cox regression analyses with adjustment and then combined.
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close to loci that are demethylated during differentiation40,41.
Although speculative, we note that the rs12374648 risk genotype
was associated with hypomethylation at the genomic region
encompassing MTHFD1L and AKAP12, suggesting a possible
mechanistic basis for the 6q25.1 association.
In addition to variation at 6q25.1, we identiﬁed suggestive
associations at six other loci, a number of which annotate genes
having strong a priori evidence for having a role in MM. Notably at
1q23.3, a region commonly ampliﬁed in MM, an association with
rs1934908 genotype is also seen to be an eQTL for FRCLA, a gene
with regulatory inﬂuence on IgG levels42. In contrast to these
suggestive associations we did not ﬁnd any evidence to support the
recent claim that variation at 16p13 deﬁned by the rare SNP
rs72773978 inﬂuences the risk of MM-OS43, Pcombined¼ 0.92,
proportional hazards model; Supplementary Table 6.
GWASs have been successful in identifying variants inﬂuencing
susceptibility for most cancers. Notably, nine common variants
have thus far been shown to be associated with MM risk14–17,19.
Paradoxically variants for cancer prognosis have been elusive and
in this study we have only identiﬁed one variant for myeloma
survival at genome-wide statistical signiﬁcance. A major reason for
the disparity is study power. Despite the size of our study, the
power to detect association with MM-OS is at best only modest.
All of the common susceptibility alleles for MM are associated with
relative risks of B1.15 and such alleles can be identiﬁed through
large case-control series, in contrast our survival analysis, based on
1,200 myeloma related deaths, had only 80% power to detect alleles
with a HR greater Z1.5 and minor allele frequency (MAF)40.2.
Our ﬁndings support the hypothesis that germline variation
inﬂuences outcome following treatment of MM. These results
provide insight into the molecular mechanisms of tumour
progression implying that germline markers of prognosis have
the potential to enhance risk stratiﬁcation. However, it is clear
that trials larger than ours are required to identify additional loci
associated with OS. Genotyping samples from future clinical
trials, is likely to be especially informative and to offer the
prospect of establishing the relationship between inherited
variants, molecular subtypes and speciﬁc therapies.
Methods
Myeloma patient samples. We pooled data from four independent MM case
series14–17 in populations of European ancestry with existing high-density SNP
genotyping (Supplementary Fig. 1): (i) UK-My11-GWAS comprising 877 MM
cases from the UK MRC Myeloma IX trial. (ii) UK-My9-GWAS comprising 1,165
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Figure 3 | Kaplan–Meier curves for MM-OS at 6q25.1 (rs12374648). Survival curves for the AA homozygotes are shown as a solid line. The red line
depicts the survival curve for the AG heterozygotes, and the dashed line depicts the survival curve for the rare homozygotes GG. Vertical ticks indicate
censored data points.
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MM cases from the UK MRC Myeloma IX trial; (iii) German-GMMG-GWAS,
comprising 511 MM patients recruited by the GMMG, coordinated by the
University Clinic, Heidelberg; (iv) US-UAMS-GWAS comprising 703 newly
diagnosed MM patients treated at the Myeloma Institute at UAMS. All of these
trials have been reported previously but importantly all include a single or double
autologous stem cell transplant as one component of the treatment44–47 (Table 2).
All studies were approved by the relevant institutional review boards, and all
participants provided written informed consent.
Table 2 | Clinical characteristics in the four patient cohorts.
UK-My9 UK-My11 GER-GMMG US-UAMS
Number of cases 1,165 877 511 703
Median age at diagnosis 64 66 57 59
Median follow-up (months) 46.7 29.8 45.2 114
48.0 (ASCT) 29.8 (ASCT)
Gender
Male 694 520 294 444
Female 471 357 217 259
ISS
I 246 231 232 332
II 475 373 168 208
III 444 273 111 163
WHO performance stage
0 302 316 177 NA
1 529 360 147 NA
2 210 139 24 NA
Z3 119 46 6 NA
NA 5 16 157 NA
Deceased
Yes 653 201 156 335
No 512 676 355 368
Disease progression
Yes 900 465 358 252
No 265 412 153 451
Autologous cell transplant 504 516 511 703
Study Intensive: 504 Intensive: 516 HD3: 81 TT2: 248
Non-intensive: 661 Non-intensive: 361 HD4: 275 TT3: 183
Non-trial: 155 TT3B: 104
TT4: 95
Non-trial: 73
Treatment received CTD: 358 CTD: 265 PAD: 175 DPACE-VAD: 128
CTDa: 215 CTDa: 184 TAD: 52 DTPACE: 151
CVAD: 346 CRD: 250 VAD: 263 MVTDPACE: 96
MP: 237 CRDa: 178 Other: 21 VDTPACE: 11
Other: 9 VDTPACEa: 182
Other: 31
Heavy chain paraprotein
IgG 635 464 297 393
IgA 226 221 116 150
IgD 23 17 4 5
LCO 134 112 82 129
None 8 6 7 11
NA/other 139 57 5 15
Light chain paraprotein
Lambda 354 260 165 417
Kappa 672 560 340 258
No light chain 0 5 0 6
NA/other 139 52 6 22
t4;14
Yes 72 81 49 NA
No 593 504 370 NA
NA 500 292 92 NA
Gain 1q21
Yes 206 161 152 NA
No 360 297 245 NA
NA 599 419 114 NA
del p53
Yes 60 41 37 NA
No 583 417 366 NA
NA 522 419 108 NA
CRD, cyclophosphamide, lenalidomide, dexamethasone; CTD, cyclophosphamide, thalidomide, dexamethasone; CVAD, cyclophosphamide, vincristine, doxorubicin, dexamethasone;
DPACE, dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide; DTPACE, examethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide and etoposide; MP, melphalan,
prednisone; MVDTPACE, melphalan, bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide; NA, not applicable; PAD, bortezomib, adriamycin, dexamethasone;
TAD, thalidomide, doxorubicin, dexamethasone; TT, total therapy; VAD, vincristine, doxorubicin and dexamethasone; VDTPACE, bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin,
cyclophosphamide, etoposide.
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Genotyping and quality control. Cases were genotyped using Illumina Human
OmniExpress-12 v1.0 arrays according to the manufacturer’s protocols (Illumina,
San Diego, USA). Standard quality control was performed on all scans, excluding
individuals with low call rate (o90%) and extremely high or low heterozygosity
(Po1.0 10 4, test of heterogeneity), as well as all individuals evaluated to be of
non-European ancestry (using the HapMap version 2 CEU, JPT/CHB and
YRI populations as a reference; Supplementary Fig. 2). A summary of the number
of genotyped SNPs and the number of SNPs passing QC is detailed in
Supplementary Fig. 1.
Imputation. Genotypes for common variants across the genome were imputed
using 1000 Genomes Project (phase 1 integrated release 3, March 2012) and
UK10K as reference in conjunction with IMPUTE2 v2.1.1 (ref. 48) after
pre-phasing with SHAPEIT software49. Poorly imputed SNPs deﬁned by an
information measure (Is)o0.90 were excluded from the analyses. All genomic
locations are given in NCBI Build 37/UCSC hg19 coordinates.
Statistical analysis. The primary end point was MM-speciﬁc OS (MM-OS).
Time-to-event was calculated from date of recruitment (left censoring) to avoid
bias from the inclusion of prevalent cases. In the German series, the follow-up was
started from transplantation, shortly after diagnosis. Follow-up was right censored
on the date of death if death was other than MM, or the date last known alive if
death did not occur. Kaplan–Meier survival curves according to genotype were
generated and the homogeneity of the survival curves between genotypes was
examined. Cox regression analysis was used to estimate genotype-speciﬁc HR and
associated 95% CI. Where necessary we controlled for cryptic population sub-
structure by including a variable number of principal components as covariates for
each data set. For each SNP HRs were generated using common allele homozygotes
as the reference group. P-values presented correspond to the signiﬁcance of a test
difference among all three of the genotype groups (common allele homozygote,
heterozygote and rare allele homozygote). For SNPs where fewer than ﬁve minor
allele homozygotes were observed, minor allele homozygote genotypes were
combined with the heterozygotes. For the statistically signiﬁcantly associated SNPs,
we ran multivariable Cox models adjusting for ISS, age and treatment where
appropriate. We conﬁned our analysis to SNPs with MAF45% because of extreme
value of the test statistics. Overall statistical signiﬁcance tests for each SNP were
performed by combining the results for each data set using a ﬁxed-effects meta-
analysis. All statistical tests were two-sided. Inﬂation of the test statistics, l, was
estimated by dividing the 45th percentile of the test statistic by 0.357—the 45th
percentile for a w2 distribution on 1 degree of freedom. Heterogeneity between
studies was quantiﬁed using the I2 statistic. Associations were regarded as statis-
tically signiﬁcant at a P value r5.0 10–8 (that is, genome-wide signiﬁcance).
Multivariable stepwise variable selection was performed using a standard back-
ward-elimination approach, variables were retained at a level of signiﬁcance
Po0.05. All statistical analyses were performed using R (v3.1.3) software50,51.
eQTL analysis. Expression quantitative trait locus (eQTL) analyses were
performed for all genes in the 1 MB region spanning the MM-OS associated SNPs
using Affymetrix Human Genome U133þ 2.0 array data for plasma cells from 184
MRC Myeloma IX trial patients, 658 GMMG patients and 604 UAMS patients,
analysis as previously described52. In addition, we surveyed the effect of genotype
on expression in other tissues using the publicly accessible GTeX (ref. 53), Blood
eQTL (ref. 54), MuTHER studies55, Framingham heart study56 and SCAN (ref. 57)
databases.
meQTL analysis. Methylation quantitative trait locus analyses of adjacent genes to
SNPs of interest using probe-level DNA methylation data generated using Illumina
450K methylation arrays on plasma cells from 365 MRC myeloma XI trial patients
(UK-My11). Association between SNP genotype and normalized methylation levels
was tested by linear regression.
Translocation detection. Conventional cytogenetic studies of MM cells were
conducted using standard karyotyping methodologies, and standard criteria for the
deﬁnition of a clone were applied. Fluorescence in situ hybridization and ploidy
classiﬁcation of UK samples was conducted using methodologies previously
described58,59. Fluorescence in situ hybridization and ploidy classiﬁcation of
GMMG samples was performed as previously described. The XL IGH Break Apart
probe (MetaSystems, Altlussheim Germany) was used to detect any IGH
translocation in GMMG60.
Bioinformatics. To explore the epigenetic proﬁle of association signals, we used
chromatin state segmentation in lymphoblastoid cell lines (LCL) data generated by
the ENCODE project. The states were inferred from ENCODE histone modiﬁca-
tion data (histone H4 Lys20 methylation (H4K20me1), H3 Lys9 acetylation
(H3K9ac), H3K4me3, H3K4me2, H3K4me1, H3K36me3, H3K27me3, H3K27ac
and CCCTC-binding factor (CTCF)) binarized using a multivariate hidden Markov
model. We used HaploReg and RegulomeDB61,62 to examine whether any of the
SNPs or their proxies (that is, r240.8 in the 1000 Genomes EUR reference panel)
annotating putative transcription factor binding or enhancer elements. We assessed
sequence conservation using Genomic Evolutionary Rate Proﬁling scores63.
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